← Leaderboards
Richard T Pomerantz
Temple Univ Of The Commonwealth
$13,012,287
Attributed
$16,554,153
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,554,153 · 15
By mechanism
R01$12,879,987 · 8
R35$1,371,884 · 1
R41$1,084,616 · 3
R00$724,200 · 1
R21$370,794 · 1
K99$122,672 · 1
Top collaborators
- Tomasz Skorski5 shared
- Steven A Benner3 shared
- Wayne E Childers2 shared
- Christine M Eischen2 shared
Most similar at Temple Univ Of The Commonwealth
Same institution · by research overlap
- Alexander V Mazin$9,841,805
Others in their field
Top investigators on “Cancer Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$394,493,843
- Gregory H Reaman · National Childhood Cancer Foundation$172,801,935
- Richard A Gibbs · Baylor College Of Medicine$159,160,442
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Mary M Horowitz · Medical College Of Wisconsin$153,900,671
- William George Nelson · Johns Hopkins University$111,434,918
Research focus
Cancer CellPolymeraseCellsMediatingMalignant NeoplasmsDna RepairDna-Directed Dna PolymeraseDouble Strand Break RepairExhibitsPathway InteractionsBiochemicalIn VitroResistanceDna DamageProteinsBaseStructureMutationGenomic InstabilityLeadHomologous RecombinationChemotherapyIn VivoCrispr/Cas Technology
Grant awards (43)
Novel Mechanisms and Regulation of Mammalian Double-Strand Break Repair$741,972
R35 · FY2025 · GM · contact PI
Development of Best-in-Class Pol-Theta Inhibitors$682,151
R01 · FY2025 · CA · contact PI
A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma$623,596
R01 · FY2025 · CA · contact PI
Development of Best-in-Class Pol-Theta Inhibitors$712,514
R01 · FY2024 · CA · contact PI
Novel Mechanisms and Regulation of Mammalian Double-Strand Break Repair$629,912
R35 · FY2024 · GM · contact PI
A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma$623,596
R01 · FY2024 · CA · contact PI
PolQ as a novel therapeutic target in AML$499,929
R01 · FY2024 · CA
PolQ as a novel therapeutic target in AML$523,880
R01 · FY2023 · CA
Mechanisms of RNA-DNA repair$377,348
R01 · FY2023 · GM · contact PI
Enzymatic Synthesis of RNA$300,000
R01 · FY2023 · HG
Enzymatic Synthesis of RNA$686,689
R01 · FY2022 · HG
PolQ as a novel therapeutic target in AML$535,835
R01 · FY2022 · CA
Structure and Function of DNA Polymerase Theta$387,899
R01 · FY2022 · GM · contact PI
Mechanisms of RNA-DNA repair$377,348
R01 · FY2022 · GM · contact PI
Enzymatic Synthesis of RNA$774,189
R01 · FY2021 · HG
PolQ as a novel therapeutic target in AML$556,097
R01 · FY2021 · CA
Structure and Function of DNA Polymerase Theta$387,897
R01 · FY2021 · GM · contact PI
Structure Based Design of Pol-theta inhibitors$385,900
R41 · FY2021 · CA · contact PI
Mechanisms of RNA-DNA repair$377,348
R01 · FY2021 · GM · contact PI
PolQ as a novel therapeutic target in AML$565,257
R01 · FY2020 · CA
Nucleotide inhibitors as precision medicine in breast cancer$399,757
R41 · FY2020 · CA · contact PI
Mechanisms of RNA-DNA repair$365,264
R01 · FY2020 · GM · contact PI
Next-generation precision medicine for targeting recombination-deficient cancers$298,959
R41 · FY2020 · CA · contact PI
Structure and Function of DNA Polymerase Theta$286,527
R01 · FY2020 · GM · contact PI
Structure and Function of DNA Polymerase Theta$113,367
R01 · FY2020 · GM · contact PI
Mechanisms of RNA-DNA repair$26,501
R01 · FY2020 · GM · contact PI
Structure and Function of DNA Polymerase Theta$406,765
R01 · FY2019 · GM · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$284,616
R01 · FY2019 · GM · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$21,272
R01 · FY2019 · GM · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$305,888
R01 · FY2018 · GM · contact PI
Targeting BRCA Deficient Cells for Killing$356,850
R01 · FY2017 · CA · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$305,888
R01 · FY2017 · GM · contact PI
Development of DNA Polymerase θ Inhibitors for Precision Medicine in BRCA Deficient Cancers$169,650
R21 · FY2017 · CA · contact PI
Targeting BRCA Deficient Cells for Killing$356,850
R01 · FY2016 · CA · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$305,888
R01 · FY2016 · GM · contact PI
Development of DNA Polymerase θ Inhibitors for Precision Medicine in BRCA Deficient Cancers$201,144
R21 · FY2016 · CA · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$90,000
R01 · FY2016 · GM · contact PI
Targeting BRCA Deficient Cells for Killing$356,850
R01 · FY2015 · CA · contact PI
Mechanisms of Mammalian Double-Strand Break Repair$305,888
R01 · FY2015 · GM · contact PI
Mechanisms and Regulation of Human Translesion DNA Polymerases$248,999
R00 · FY2015 · CA · contact PI
Mechanisms and Regulation of Human Translesion DNA Polymerases$241,142
R00 · FY2014 · CA · contact PI
Mechanisms and Regulation of Human Translesion DNA Polymerases$234,059
R00 · FY2013 · CA · contact PI
Mechanisms and Regulation of Human Translesion DNA Polymerases$122,672
K99 · FY2012 · CA · contact PI